On November 11, the four-day Second World Health Expo was held in Wuhan International Expo Center. This year's health expo set up 12 specialized pavilions, such as Anti-epidemic Materials Pavilion, Medical Equipment Pavilion, Biochemical Drugs Pavilion, and Medical Science and Technology Pavilion. Renfo Pharmaceuticals presented the latest R&D results of Class 1 new drug “Remazolam Benzenesulfonate” and Alfentanil at the Health Expo.
　　It is understood that remazolam benzenesulfonate was officially approved in July this year, for painless diagnosis and treatment sedation, general anesthesia, ICU sedation and local anesthesia sedation and other fields, the listing of this drug broke the domestic and foreign clinically widely used in the field of sedative drugs in the last 30 years no innovative drugs on the market, but also is the first approved in Hubei Province of the chemical class 1 new drugs; alfentanil was approved in March this year, as a narcotic analgesic used for induction of general anesthesia, it is used for the induction of general anesthesia. Alfentanil was approved in March this year, which is used as a narcotic analgesic for induction and maintenance of general anesthesia. After the listing of this drug, Renfo Pharma became the largest R&D and production base of anesthetic drugs in Asia and the only R&D and production enterprise of the whole fentanyl system in China.
　　As the curator of A4 Biochemical Drugs Pavilion, more than 10 enterprises of Renfo Pharmaceuticals Group, including Yichang Renfo, Gedian Renfo, Jiulong Renfo, Wuhan Renfo, Xinjiang Uygur Pharmaceuticals, Kangle Pharmaceuticals, Biannual Kangxin, Renfo Fukang and Zhengzhou Bosai, participated in the exhibition with a total of more than 40 products.
　　In Wuhan, biopharmaceutical and medical device enterprises are an important pillar industry. It is reported that Wuhan has attracted more than 1,500 biopharmaceutical and medical device enterprises, such as Pfizer of the U.S., Bayer of Germany and other Fortune 500 and Renfu Pharmaceutical Group and other large pharmaceutical companies. At present, Renfu Pharmaceutical has formed an industrial layout of drug R&D center, drug production base, drug distribution and sales center in Wuhan.
　　“As the leading enterprise of pharmaceutical industry in Hubei Province, Renfu Pharmaceutical Group will effectively play a good role in leading and driving the industry, based on Hubei, layout the whole country, and go to the world, adhere to the introduction and go out, take the domestic large cycle as the main body, promote the domestic and international double cycle, and continuously improve the development of large health industry in Hubei Province and Wuhan City.” Deng Xiafei, president of Renfu Pharmaceutical Group, said.